Given the similarity of pathophysiology of primary and secondary HLH, currently ongoing and future studies will contribute to define the precise role of this IFNγ neutralizing antibody in controlling HLH manifestations occurring in the context of rheumatologic disorders or malignancies. The gene discussed is IFNG; the disease is hemophagocytic syndrome.